{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:35:25Z","timestamp":1783366525444,"version":"3.54.6"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P30GM106392"],"award-info":[{"award-number":["P30GM106392"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["U54 GM104940"],"award-info":[{"award-number":["U54 GM104940"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.phrs.2022.106470","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T11:46:06Z","timestamp":1664797566000},"page":"106470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Difelikefalin, a peripherally restricted KOR (kappa opioid receptor) agonist, produces diuresis through a central KOR pathway"],"prefix":"10.1016","volume":"185","author":[{"given":"Jacob K.","family":"Meariman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C.","family":"Sutphen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald E.","family":"Mercante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Kapusta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4531","key":"10.1016\/j.phrs.2022.106470_bib1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1126\/science.6120570","article-title":"Dynorphin is a specific endogenous ligand of the \u03ba opioid receptor","volume":"215","author":"Chavkin","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.phrs.2022.106470_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.05.025","article-title":"Non-addictive orally-active kappa opioid agonists for the treatment of peripheral pain in rats","volume":"856","author":"Beck","year":"2019","journal-title":"Eur. J. Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2022.106470_bib3","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1159\/000447911","article-title":"Kappa-Opioid agonist U50,488H-mediated protection against heart failure following myocardial ischemia\/reperfusion: dual roles of heme oxygenase-1","volume":"39","author":"Tong","year":"2016","journal-title":"Cell Physiol. Biochem."},{"issue":"3","key":"10.1016\/j.phrs.2022.106470_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00210-008-0358-8","article-title":"Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: Nalfurafine, U50,488H, and salvinorin A","volume":"379","author":"Inan","year":"2009","journal-title":"Naunyn Schmiede Arch. Pharm."},{"issue":"4765","key":"10.1016\/j.phrs.2022.106470_bib5","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by \u03ba opiate receptors","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"issue":"37","key":"10.1016\/j.phrs.2022.106470_bib6","doi-asserted-by":"crossref","first-page":"12917","DOI":"10.1523\/JNEUROSCI.2444-15.2015","article-title":"Kappa opioid receptor-induced aversion requires p38 MAPK activation in VTA dopamine neurons","volume":"35","author":"Ehrich","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2022.106470_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","article-title":"Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor","volume":"32","author":"Schattauer","year":"2017","journal-title":"Cell Signal."},{"issue":"4","key":"10.1016\/j.phrs.2022.106470_bib8","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol. Dial. Transpl."},{"issue":"3","key":"10.1016\/j.phrs.2022.106470_bib9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"2.1","key":"10.1016\/j.phrs.2022.106470_bib10","article-title":"kappa-Opioid agonist inhibition of osmotically induced AVP release: preferential action at hypothalamic sites","volume":"270","author":"Rossi","year":"1996","journal-title":"Am. J. Physiol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106470_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)23461-9","article-title":"Diuresis and suppression of vasopressin by kappa opioids: comparison with mu and delta opioids and clonidine","volume":"234","author":"Leander","year":"1985","journal-title":"J. Pharm. Exp. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2022.106470_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1476-5381.1986.tb11160.x","article-title":"On the mechanisms of kappa-opioid-induced diuresis","volume":"89","author":"Blackburn","year":"1986","journal-title":"Br. J. Pharm."},{"issue":"4","key":"10.1016\/j.phrs.2022.106470_bib13","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.1476-5381.1989.tb12659.x","article-title":"Studies on the adrenomedullary dependence of kappa-opioid agonist-induced diuresis in conscious rats","volume":"98","author":"Borkowski","year":"1989","journal-title":"Br. J. Pharm."},{"issue":"4","key":"10.1016\/j.phrs.2022.106470_bib14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0091-3057(98)00124-5","article-title":"Sex differences in discriminative stimulus and diuretic effects of the kappa opioid agonist U69,593 in the rat","volume":"61","author":"Craft","year":"1998","journal-title":"Pharm. Biochem. Behav."},{"issue":"46\u20134","key":"10.1016\/j.phrs.2022.106470_bib15","article-title":"Cardiovascular and renal responses produced by central orphanin FQ\/nociceptin occur independent of renal nerves","volume":"277","author":"Kapusta","year":"1999","journal-title":"Am. J. Physiol. - Regul. Integr. Comp. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106470_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1124\/jpet.110.175398","article-title":"Microinjection of glycine into the hypothalamic paraventricular nucleus produces diuresis, natriuresis, and inhibition of central sympathetic outflow","volume":"337","author":"Krowicki","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2022.106470_bib17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1161\/HYPERTENSIONAHA.121.18503","article-title":"Nalfurafine, a G-protein\u2013biased KOR (Kappa Opioid Receptor) agonist, enhances the diuretic response and limits electrolyte losses to standard-of-care diuretics","volume":"79","author":"Meariman","year":"2022","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.phrs.2022.106470_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0306-4522(99)00472-8","article-title":"The kappa opioid receptor and dynorphin co-localize in vasopressin magnocellular neurosecretory neurons in guinea-pig hypothalamus","volume":"96","author":"Shuster","year":"2000","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.phrs.2022.106470_bib19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0006-8993(01)02154-0","article-title":"Localization of kappa opioid receptors in oxytocin magnocellular neurons in the paraventricular and supraoptic nuclei","volume":"898","author":"Smith","year":"2001","journal-title":"Brain Res."},{"issue":"11","key":"10.1016\/j.phrs.2022.106470_bib20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1046\/j.1365-2826.1999.00419.x","article-title":"Kappa-opioid receptor activation inhibits post-spike depolarizing after-potentials in rat supraoptic nucleus neurones in vitro","volume":"11","author":"Brown","year":"1999","journal-title":"J. Neuroendocr."},{"issue":"1","key":"10.1016\/j.phrs.2022.106470_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)39398-5","article-title":"Central kappa opioid receptor-evoked changes in renal function in conscious rats: participation of renal nerves","volume":"267","author":"Kapusta","year":"1993","journal-title":"J. Pharm. Exp. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2022.106470_bib22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0022-3565(25)20709-1","article-title":"Role of renal nerves in excretory responses to administration of kappa agonists in conscious spontaneously hypertensive rats","volume":"251","author":"Kapusta","year":"1989","journal-title":"J. Pharm. Exp. Ther."},{"issue":"24","key":"10.1016\/j.phrs.2022.106470_bib23","doi-asserted-by":"crossref","first-page":"25002","DOI":"10.1074\/jbc.M313366200","article-title":"kappa Opioid receptor interacts with Na(+)\/H(+)-exchanger regulatory factor-1\/Ezrin-radixin-moesin-binding phosphoprotein-50 (NHERF-1\/EBP50) to stimulate Na(+)\/H(+) exchange independent of G(i)\/G(o) proteins","volume":"279","author":"Huang","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2022.106470_bib24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s13318-015-0286-1","article-title":"Drug-drug interactions of a novel \u03ba-opioid receptor agonist, nalfurafine hydrochloride, involving the P-glycoprotein","volume":"41","author":"Ando","year":"2016","journal-title":"Eur. J. Drug Metab. Pharm."},{"issue":"11","key":"10.1016\/j.phrs.2022.106470_bib25","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1211\/0022357991776985","article-title":"Kappa-opioid receptors behind the blood-brain barrier are involved in the anti-hypertensive effects of systemically administered kappa-agonists in the conscious spontaneously hypertensive rat","volume":"51","author":"Shen","year":"1999","journal-title":"J. Pharm. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2022.106470_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0196-9781(94)90180-5","article-title":"Comparative effects of intrahippocampal injection of dynorphin A(1-8), dynorphin A(1-13), dynorphin A(1-17), U-50,488H, and dynorphin B on blood pressure and heart rate in spontaneously hypertensive and normotensive Wistar-Kyoto rats","volume":"15","author":"Wang","year":"1994","journal-title":"Peptides"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822004169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822004169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:34:06Z","timestamp":1778582046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822004169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":26,"alternative-id":["S1043661822004169"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106470","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Difelikefalin, a peripherally restricted KOR (kappa opioid receptor) agonist, produces diuresis through a central KOR pathway","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106470"}}